1-2 of 2
Lisa Ann Nardelli, BS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS)

Jeffrey E. Lancet, MD, Rami S Komrokji, MD, Kendra L. Sweet, MD, Vu H. Duong, MD, Kathy L McGraw, PhD, Ling Zhang, MD, Lisa Ann Nardelli, BS, Zhenjun Ma, PhD, Richard R Reich, PhD, Eric Padron, MD, Alan F List, MD
Journal: Blood
Blood (2016) 128 (22): 3174.
https://doi.org/10.1182/blood.V128.22.3174.3174
Published: 2016
Journal Articles

Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F List, MD, Zhuoxin Sun, PhD, Amit Verma, MD, John M. Bennett, MD, Kathy L McGraw, PhD, Lisa Ann Nardelli, BS, Jaroslaw P Maciejewski, MD PhD FACP, Jessica K Altman, MD, Puneet Cheema, MD, David F. Claxton, MD, Rami S. Komrokji, MD, Selina Luger, MD, Ryan Mattison, MD, Tim Wassenaar, MD, Andrew Artz, MD, Charles A Schiffer, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2016) 128 (22): 223.
https://doi.org/10.1182/blood.V128.22.223.223
Published: 2016